Effect of orlistat and anti-androgen oral contraceptives on pregnancy outcomes in overweight or obese PCOS patients during comprehensive management - PubMed

4 hours ago

Study investigates the impact of combined oral contraceptives (COCs) and orlistat on pregnancy outcomes in overweight or obese women with PCOS.
Participants were divided into three groups: DRSP/EE monotherapy, DRSP/EE + orlistat combination therapy, and a non-medication control group.
Combination therapy significantly reduced the incidence of gestational diabetes mellitus (GDM) compared to the control group (31.9% vs. 56.6%).
DRSP/EE monotherapy showed a decreasing trend in GDM incidence but was not statistically significant after adjustments.
No significant differences were found in hypertensive disorders of pregnancy (HDP), live birth rates, or adverse pregnancy outcomes (APO) among groups.
Combination therapy group had the highest live birth rate (97.2%) and the lowest APO rate (21.1%).
Neonatal outcomes (preterm delivery, low birth weight, macrosomia) were comparable across groups, with combination therapy showing numerically better results.
BMI, fasting plasma glucose (FPG), fasting insulin (FINS), and total testosterone (TT) were identified as independent risk factors for GDM.
Both medication regimens were significant protective factors against GDM.
Comprehensive management targeting BMI and metabolic indicators is crucial for improving pregnancy prognosis in overweight or obese PCOS women.

Hasty Briefsbeta